

Revision date: 18-Aug-2015

Version: 2.5

Page 1 of 7

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: VANGUARD DAP

Trade Name: Synonyms:	Vanguard DAP Canine Distemper-Adenovirus Type 2-Parainfluenza Vaccine, Modified Live Virus VANGUARD DA2PI
Chemical Family:	Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against Intended Use: Veterinary Vaccine Restrictions on Use: Not for human use

Details of the Supplier of the Safety Data Sheet

Zoetis Inc.Zoetis B100 Campus Drive, P.O. Box 651MercuriuFlorham Park, New Jersey 07932 (USA)1930 ZavRocky Mountain Poison and Drug Center Phone: 1-866-531-8896BelgiumProduct Support/Technical Services Phone: 1-800-366-52881930 Zav

Emergency telephone number: CHEMTREC (24 hours): 1-800-424-9300 Contact E-Mail: VMIPSrecords@zoetis.com

Classification of the Substance or Mixture

Zoetis Belgium S.A. Mercuriusstraat 20 1930 Zaventem Belgium

Emergency telephone number: International CHEMTREC (24 hours): +1-703-527-3887

2. HAZARDS IDENTIFICATION

Freeze-dried preparation plus sterile diluent

Not classified as hazardous
Not Classified Non-hazardous in accordance with international standards for workplace safety.
In the event of accidental injection, an allergic reaction may occur. Signs and symptoms might include skin rash, itching, redness or swelling. Respiratory reactions may be characterized by rhinitis, sneezing, scratchy throat, oral mucosal edema, laryngeal mucosal edema, coughing, shortness of breath, wheezing, and chest pain. Asthma like reactions occur with acute exposures in sensitized patients. If an allergic reaction occurs, the worker should be removed to the nearest emergency room and the appropriate therapy instituted. Non-Hazardous Substance. Non-Dangerous Goods.

Appearance:

Note:

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS	GHS Classification	%
		List		
Gentamicin	1403-66-3	215-765-8	Not Listed	##

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Canine Distemper	NOT ASSIGNED	Not Listed	Not Listed	*
Canine Adenovirus Type 2	NOT ASSIGNED	Not Listed	Not Listed	*
Canine Parainfluenza	NOT ASSIGNED	Not Listed	Not Listed	*

Additional Information:

* Proprietary

Trace

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

4. FIRST AID MEASURES

Description of First Aid Measures Eye Contact:	Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.
Skin Contact:	Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.
Ingestion:	Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.
Inhalation:	Remove to fresh air and keep patient at rest. Seek medical attention immediately.
Most Important Symptoms and Effect Symptoms and Effects of Exposure: Medical Conditions Aggravated by Exposure:	cts, Both Acute and Delayed For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information. None known
Indication of the Immediate Medical Notes to Physician:	Attention and Special Treatment Needed None

5. FIRE-FIGHTING MEASURES

Extinguishing Media:

Extinguish fires with CO2, extinguishing powder, foam, or water.

Material Name: VANGUARD DAP Revision date: 18-Aug-2015

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Formation of toxic gases is possible during heating or fire. Products:

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting:	Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.
Additional Consideration for Large Spills:	Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

When handling, use appropriate personal protective equipment (see Section 8). Minimize dust generation and accumulation. Avoid breathing dust, vapor or mist. Avoid contact with eyes, skin and clothing. Avoid accidental injection. Wash thoroughly after handling. Releases to the environment should be avoided.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions:	Store under refrigeration in closed container.
Storage Temperature:	2-7°C
Incompatible Materials:	This material can be denatured or inactivated by a variety of organic solvents, salts or heavy
	metals.
Specific end use(s):	No data available

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

Gentamicin

Bulgaria OEL - TWA

0.1 mg/m³

The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.

Gentamicin

Zoetis OEB

OEB 2 (control exposure to the range of 100ug/m³ to < 1000ug/m³)

8. EXPO	SURE CONTROLS / PERSONAL PROTECTION
Exposure Controls	
Engineering Controls:	Engineering controls should be used as the primary means to control exposures. Keep air contamination levels below the exposure limits or within the OEB range listed above in this section. General room ventilation is adequate unless the process generates dust, mist or fumes.
Personal Protective Equipment:	Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).
Hands:	Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.
Eyes:	Wear safety glasses or goggles if eye contact is possible.
Skin:	Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.
Respiratory protection:	None required under normal conditions of use. Whenever excessive air contamination (dust, mist, vapor) is generated, respiratory protection, with appropriate protection factors, should be used to minimize exposure. If airborne exposures are within or exceed the Occupational Exposure Band (OEB) range, wear an appropriate respirator with a protection factor sufficient to control exposures to the bottom of the OEB range.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Odor: Molecular Formula:	Freeze-dried preparation p diluent No data available. Mixture	lus sterile	Color: Odor Threshold: Molecular Weight:	No data available. No data available. Mixture
Solvent Solubility: Water Solubility: pH: Melting/Freezing Point (°C): Boiling Point (°C): Partition Coefficient: (Method, pH, E No data available Decomposition Temperature (°C): Evaporation Rate (Gram/s): Vapor Pressure (kPa): Vapor Density (g/ml): Relative Density: Specific Gravity: Viscosity:	No data available No data available 7.0 +/- 1.5 No data available >100 ndpoint, Value) No data available. No data available Expected to be negligible No data available No data available 1.0 +/-0.2 No data available	e		
Flammablity: Autoignition Temperature (So Flammability (Solids): Flash Point (Liquid) (°C): Upper Explosive Limits (Liqui Lower Explosive Limits (Liqui Polymerization:	lid) (°C): d) (% by Vol.):	No data avai No data avai No data avai No data avai No data avai Will not occu	lable lable lable lable	

10. STABILITY AND REACTIVITY

Reactivity:

No data available

e under normal conditions of use.
ata available
at 2°-7°C. Prolonged exposure to higher temperatures may adversely affect potency. Do eeze.
material can be denatured or inactivated by a variety of organic solvents, salts or heavy s.
expected under normal conditions.

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information:

Toxicological properties of the formulation have not been investigated. The information in this section describes the potential hazards of the individual ingredients and the formulation. The antigens included in this product are non-infectious. All have been prepared from modified or inactivated preparations of microorganisms. Routes of exposure: eye contact, skin contact

Acute Toxicity: (Species, Route, End Point, Dose)

Gentamicin

RatOralLD506600 mg/kgRatSubcutaneousLD50710mg/kgMouseIMLD50167 mg/kgRatIMLD50463 mg/kg

Inhalation Acute Toxicity Allergic reactions might occur based on effects of the individual components.

Irritation / Sensitization: (Study Type, Species, Severity)

Gentamicin

Eye Irritation Rabbit Non-irritating

Skin Irritation / Sensitization May cause allergic reactions in susceptible individuals.

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Gentamicin

Embryo / Fetal Development Rat Intramuscular 75 mg/kg/day LOAEL Developmental toxicity,

Carcinogen Status:

None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

12. ECOLOGICAL INFORMATION

Environmental Overview:	The environmental characteristics of this material have not been fully evaluated. Releases to the environment should be avoided.
Toxicity:	No data available
Persistence and Degradability:	No data available
Bio-accumulative Potential:	No data available
Mobility in Soil:	No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods:

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Canada - WHMIS: Classifications WHMIS hazard class: Non-controlled This product has been classified in accordance with the hazard criteria of the CPR and the SDS contains all of the information required by the CPR.

Gentamicin

CERCLA/SARA 313 Emission reporting California Proposition 65

Not Listed Not Listed

15. REGULATORY INFORMATION		
Australia (AICS):	Present	
Standard for the Uniform Scheduling	Schedule 4	
for Drugs and Poisons:		
EU EINECS/ELINCS List	215-765-8	
Canine Distemper		
CERCLA/SARA 313 Emission reporting	Not Listed	
California Proposition 65	Not Listed	
EU EINECS/ELINCS List	Not Listed	
Canine Adenovirus Type 2		
CERCLA/SARA 313 Emission reporting	Not Listed	
California Proposition 65	Not Listed	
EU EINECS/ELINCS List	Not Listed	
Canine Parainfluenza		
CERCLA/SARA 313 Emission reporting	Not Listed	
California Proposition 65	Not Listed	
EU EINECS/ELINCS List	Not Listed	

16. OTHER INFORMATION

Data Sources:	The data contained in this SDS may have been gathered from confidential internal sources, raw material suppliers, or from the published literature.
Reasons for Revision:	Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 2 - Hazard Identification. Updated Section 11 - Toxicology Information.
Prepared by:	Toxicology and Hazard Communication Zoetis Global Risk Management

Zoetis Inc. believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet